Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.13

Mkt cap

467M

Volume

3.3M

High

2.38

P/E Ratio

-3.54

52-wk high

3.40

Low

2.13

Div yield

N/A

52-wk low

1.15

Esperion Therapeutics Inc's (NASDAQ:ESPR) stock is trading higher after the FDA approved new label expansions for its drugs NEXLETOL and NEXLIZET, based on CLEAR Outcomes data. These expansions include indications for cardiovascular risk reduction and LDL-C lowering in primary and secondary prevention patients. The approvals make over 70 million patients eligible for these treatments. The company also anticipates a final determination from the European Medicines Agency on label expansions in Europe by the second quarter of 2024.

Portfolio Pulse from Vandana Singh

March 25, 2024 | 1:24 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Landos Biopharma (LABP) led the gainers with a 181.6% increase, attributed to its Q4 earnings release. Other notable gainers include Altamira Therapeutics (CYTO), Esperion Therapeutics (ESPR), Salarius Pharmaceuticals (SLRX), Neuronetics (STIM), and Nkarta (NKTX), with their stocks rising due to various factors including Q4 earnings reports. On the losing side, SINTX Techs (SINT) experienced the largest drop of 46.5%, followed by declines in Akanda (AKAN), Trxade Health (MEDS), Nuvation Bio (NUVB), Yield10 Bioscience (YTEN), and Virios Therapeutics (VIRI).

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 1:05 pm

MicroAlgo Inc. (MLGO) shares surged 102% following the announcement of a new deep clustering algorithm. Masmi (MASI) shares rose 15% after the company considered separating its consumer business. Esperion (ESPR) shares increased 26% after FDA approval for NEXLETOL and NEXLIZET for heart attack and cardiovascular procedure prevention.

Portfolio Pulse from ryanfaloona@benzinga.com

March 25, 2024 | 12:40 pm

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) shares surged 31.4% in pre-market trading following a narrower Q4 net loss compared to the previous year. Other stocks also showed significant movement in pre-market trading, with notable gainers including Next.e.GO N.V. (NASDAQ:EGOX) and MicroAlgo Inc. (NASDAQ:MLGO), and losers such as Sintx Technologies, Inc. (NASDAQ:SINT) and Invivyd, Inc. (NASDAQ:IVVD).

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 12:03 pm

Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained an $8 price target.